RT Journal Article
T1 Effect of Empagliflozin on Heart Failure Outcomes After Acute Myocardial Infarction: Insights From the EMPACT-MI Trial
A1 Hernandez, Adrian F
A1 Udell, Jacob A
A1 Jones, W Schuyler
A1 Anker, Stefan D
A1 Petrie, Mark C
A1 Harrington, Josephine
A1 Mattheus, Michaela
A1 Seide, Svenja
A1 Zwiener, Isabella
A1 Amir, Offer
A1 Bahit, M Cecilia
A1 Bauersachs, Johann
A1 Bayes-Genis, Antoni
A1 Chen, Yundai
A1 Chopra, Vijay K
A1 A Figtree, Gemma
A1 Ge, Junbo
A1 G Goodman, Shaun
A1 Gotcheva, Nina
A1 Goto, Shinya
A1 Gasior, Tomasz
A1 Jamal, Waheed
A1 Januzzi, James L
A1 Jeong, Myung Ho
A1 Lopatin, Yuri
A1 Lopes, Renato D
A1 Merkely, Béla
A1 Parikh, Puja B
A1 Parkhomenko, Alexander
A1 Ponikowski, Piotr
A1 Rosselló, Xavier
A1 Schou, Morten
A1 Simic, Dragan
A1 Steg, Philippe Gabriel
A1 Szachniewicz, Joanna
A1 van der Meer, Peter
A1 Vinereanu, Dragos
A1 Zieroth, Shelley
A1 Brueckmann, Martina
A1 Sumin, Mikhail
A1 Bhatt, Deepak L
A1 Butler, Javed
AB Empagliflozin reduces the risk of heart failure (HF) events in patients with type 2 diabetes at high cardiovascular risk, chronic kidney disease, or prevalent HF irrespective of ejection fraction. Whereas the EMPACT-MI trial (Effect of Empagliflozin on Hospitalization for Heart Failure and Mortality in Patients With Acute Myocardial Infarction) showed that empagliflozin does not reduce the risk of the composite of hospitalization for HF and all-cause death, the effect of empagliflozin on first and recurrent HF events after myocardial infarction is unknown.EMPACT-MI was a double-blind, randomized, placebo-controlled, event-driven trial that randomized 6522 patients hospitalized for acute myocardial infarction at risk for HF on the basis of newly developed left ventricular ejection fraction of <45% or signs or symptoms of congestion to receive empagliflozin 10 mg daily or placebo within 14 days of admission. In prespecified secondary analyses, treatment groups were analyzed for HF outcomes.Over a median follow-up of 17.9 months, the risk for first HF hospitalization and total HF hospitalizations was significantly lower in the empagliflozin compared with the placebo group (118 [3.6%] versus 153 [4.7%] patients with events; hazard ratio, 0.77 [95% CI, 0.60, 0.98]; P=0.031, for first HF hospitalization; 148 versus 207 events; rate ratio, 0.67 [95% CI, 0.51, 0.89]; P=0.006, for total HF hospitalizations). Subgroup analysis showed consistency of empagliflozin benefit across clinically relevant patient subgroups for first and total HF hospitalizations. The need for new use of diuretics, renin-angiotensin modulators, or mineralocorticoid receptor antagonists after discharge was less in patients randomized to empagliflozin versus placebo (all P<0.05).Empagliflozin reduced the risk of HF in patients with left ventricular dysfunction or congestion after acute myocardial infarction.URL: https://www.clinicaltrials.gov; Unique identifier: NCT04509674.
PB American Heart Association
YR 2024
FD 2024-05-21
LK https://hdl.handle.net/20.500.13003/20976
UL https://hdl.handle.net/20.500.13003/20976
LA eng
NO Hernandez AF, Udell JA, Jones WS, Anker SD, Petrie MC, Harrington J, et al. Effect of Empagliflozin on Heart Failure Outcomes After Acute Myocardial Infarction: Insights From the EMPACT-MI Trial. Circulation. 2024 May 21;149(21):1627–38.
DS Docusalut
RD 13 jul. 2026